Retatrutide Research Highlights (2026) Obesity Research A phase 2 trial in 338 adults with obesity or overweight showed dose-dependent weight loss
This innovative GLP-1 and GIP receptor agonist has been hailed as a breakthrough for individuals struggling with obesity and type 2 diabetes
Heart failure with preserved ejection fraction (HFpEF) mice exhibit significant abnormal activation of ferroptosis, and inhibition of ferroptosis could improve the HFpEF phenotype
Current Opinion in Biotechnology , 32 , 2127
At a recent Bord Bia dairy markets seminar, Nicholas Fereday, executive director at Rabobank Research said the rise of weight-loss drugs is an evolving subject that is changing on a daily basis
In 2024, an update from the 3rd International PTDM Consensus Meeting recommended screening for diabetes risk factors with a pretransplant OGTT while the individual is on the waitlist, followed by early OGTT at 3 months posttransplantation to diagnose PTDM and a late OGTT at 1 year and onward as appropriate (279)
